Bromocriptine Therapeutic Uses and Guidelines

Introduction to Bromocriptine Therapy

The American College of Cardiology suggests the potential use of bromocriptine in women with severe acute heart failure caused by peripartum cardiomyopathy (PPCM) with left ventricular ejection fraction (LVEF) <35% 1, 2
The European Society of Cardiology endorses the "BOARD" protocol (Bromocriptine, Oral HF therapy, Anticoagulation, vasoRelaxing agents, Diuretics) for acute PPCM management, with bromocriptine dosing based on limited studies: 2.5 mg twice daily for 2 weeks, followed by 2.5 mg daily for 4 weeks 1, 3, 4

For resistant cases of hyperprolactinemia, cabergoline is now preferred over bromocriptine due to better efficacy and side effect profile, as recommended by the Endocrine Society 5, 6
The Endocrine Society suggests that for prolactinomas, withdrawal after 2+ years may be considered if prolactin levels normalize and no visible tumor remains 7

Common side effects of bromocriptine include gastrointestinal intolerance, postural hypotension, and psychological effects such as mood changes, depression, aggression, hypersexuality, and impulse control disorder, according to the American College of Cardiology 5
Echocardiography monitoring may be required for higher doses used in prolactinomas, as recommended by the European Society of Cardiology 7

Para mujeres con insuficiencia cardíaca aguda severa por cardiomiopatía periparto (PPCM) con fracción de eyección del ventrículo izquierdo (FEVI) <35%, el protocolo "BOARD" recomienda 2.5 mg dos veces al día por 2 semanas, seguido de 2.5 mg diarios por 4 semanas, según la European Journal of Heart Failure 8
Un estudio piloto mostró recuperación de FEVI de 27% a 58% a los 6 meses con bromocriptina versus 27% a 36% con tratamiento estándar (P=0.012), según la European Journal of Heart Failure 8
Se recomienda anticoagulación obligatoria en todas las pacientes con PPCM y FEVI baja que reciben bromocriptina, debido a reportes de infarto de miocardio asociados al uso del medicamento, según la European Journal of Heart Failure 8

En pacientes con enfermedad renal crónica, bromocriptina debe usarse con precaución debido a falta de estudios de seguridad, según el American Journal of Kidney Diseases 9
No se ha reportado evidencia de aumento en tasas de aborto o malformaciones congénitas en más de 1400 mujeres que tomaron el medicamento durante las primeras semanas de embarazo, según la European Journal of Heart Failure 8

The Endocrine Society recommends baseline echocardiogram before initiating high-dose bromocriptine therapy, with annual echocardiography for doses >2 mg/week and every 5 years for doses ≤2 mg/week 10, 11
Surgical intervention should be considered if vision deteriorates or fails to improve on medical therapy, or if dopamine agonist resistance, escape, or intolerance occurs, as suggested by the Endocrine Society 10, 11